Trial
NCT03961815
Open-label Extension Study of Brazikumab in Crohn's Disease
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Crohn's Disease
Intervention
Brazikumab Induction Dose
Why stopped
Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-01